(Q37776225)

23 August 2017

1 reference

title

Human myeloid dendritic cells for cancer therapy: does maturation matter? (English)

1 reference

23 August 2017

Human myeloid dendritic cells for cancer therapy: Does maturation matter? (English)

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2010.05.042

12 June 2024

1 reference

Katerina Skalova

1

1 reference

23 August 2017

Klara Mollova

series ordinal

2

1 reference

23 August 2017

Jaroslav Michalek

series ordinal

3

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

23 August 2017

19 July 2010

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20665974

full work available at URL

12 June 2024

https://api.elsevier.com/content/article/PII:S0264410X10007401?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2010.05.042

https://api.elsevier.com/content/article/PII:S0264410X10007401?httpAccept=text/plain

12 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2010.05.042

12 June 2024

1 reference

23 August 2017

volume

28

1 reference

23 August 2017

issue

32

1 reference

23 August 2017

page(s)

5153-5160

1 reference

Characterization of human blood dendritic cell subsets

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Development of dendritic-cell lineages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Harnessing human dendritic cell subsets to design novel vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Dendritic cells in rheumatoid arthritis: Which subset should be used as a tool to induce tolerance?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Interleukin-12: a cytokine at the interface of inflammation and immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Dendritic cells as therapeutic vaccines against cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Manipulating dendritic cell biology for the active immunotherapy of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Immunobiology of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

The cell biology of antigen presentation in dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Activation of dendritic cells by toll-like receptors and C-type lectins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Mobilizing dendritic cells for tolerance, priming, and chronic inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Helping the CD8(+) T-cell response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Antigen presentation and T cell stimulation by dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Dendritic cell vaccination and immune monitoring.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

The anticancer immune response: indispensable for therapeutic success?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

The immunogenicity of dendritic cell-based vaccines is not hampered by doxorubicin and melphalan administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Immunotherapy and chemotherapy--a practical partnership

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Current approaches in dendritic cell generation and future implications for cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Role of the cytokine environment and cytokine receptor expression on the generation of functionally distinct dendritic cells from human monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

IFN-alpha in the generation of dendritic cells for cancer immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

The chemokine receptor CCR7 activates in dendritic cells two signaling modules that independently regulate chemotaxis and migratory speed

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

IL-23 and IL-12p70 production by monocytes and dendritic cells in primary HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Tolerogenic dendritic cells: cytokine modulation comes of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Dendritic cells and cytokines in human inflammatory and autoimmune diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

What it takes to become an effector T cell: the process, the cells involved, and the mechanisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Proliferating dendritic cell progenitors in human blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Cross-linking cell surface chemokine receptors leads to isolation, activation, and differentiation of monocytes into potent dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Monocyte enrichment from leukapharesis products for the generation of DCs by plastic adherence, or by positive or negative selection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Isolation of monocytes from whole blood-derived buffy coats by continuous counter-flow elutriation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Large-Scale Immunomagnetic Selection of CD14+Monocytes to Generate Dendritic Cells for Cancer Immunotherapy: A Phase I Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Generation of a dendritic cell-based vaccine in chronic lymphocytic leukaemia using CliniMACS platform for large-scale production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Combination of Cobe AutoPBSC and Gambro Elutra as a platform for monocyte enrichment in dendritic cell (DC) therapy: clinical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Dendritic cells in cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Human dendritic cells. Enrichment and characterization from peripheral blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Maturation of dendritic cells by bacterial immunomodulators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Progress on new vaccine strategies for the immunotherapy and prevention of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Inhibition of human macrophage colony formation by interleukin 4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Dendritic cell immunotherapy: mapping the way.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Inducing long-term survival with lasting anti-tumor immunity in treating B cell lymphoma by a combined dendritic cell-based and hydrodynamic plasmid-encoding IL-12 gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Dendritic cell fusion vaccines for cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Sensing pathogens and tuning immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Regulation of dendritic cell function through toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Plasticity of dendritic cell function in response to prostaglandin E2 (PGE2) and interferon-gamma (IFN-gamma).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Semi-mature IL-12 secreting dendritic cells present exogenous antigen to trigger cytolytic immune responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Functional characterization of monocyte-derived dendritic cells generated under serumfree culture conditions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Phenotypic and functional characterization of mature dendritic cells from pediatric cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.042

Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts

7 January 2021

series ordinal

90

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2010.05.042

12 June 2024

Identifiers

1 reference

23 August 2017

1 reference